New Enterprise Associates‘ Venture Partner Scott Gottlieb has been nominated by President Donald J. Trump to serve as Commissioner of the U.S. Food and Drug Administration (FDA).
A physician, policy expert, and champion of health care entrepreneurship and the opportunities enabled by innovation in medical care, Dr. Gottlieb has held senior positions at the FDA and the Centers for Medicare and Medicaid Services.
In his most recent government role, he served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs. Dr. Gottlieb has been a member of NEA’s healthcare investing team since leaving the FDA in 2007.
He is a frequent contributor to The Wall Street Journal and serves as a resident fellow at the American Enterprise Institute. Dr. Gottlieb also serves as an advisor to the National Coalition for Cancer Survivorship, and is a member of the policy board to the Society of Hospital Medicine.
He was appointed by the U.S. Senate to serve on the Federal Health IT Policy Committee.
Earlier in his career, Dr. Gottlieb worked as a healthcare analyst for the investment bank Alex. Brown & Sons. He completed a residency in internal medicine at the Mount Sinai Medical Center in New York and is a graduate of the Mount Sinai School of Medicine and of Wesleyan University, in Middletown, Connecticut, where he studied Economics.